Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

FORTIFI-HN01: Et fase 2/3-studie af Ficerafusp Alfa (BCA101) eller placebo i kombination med Pembrolizumab i førstelinje PD-L1-pos, R eller M HNSCC (FORTIFI-HN01)

28. oktober 2026 opdateret af: Bicara Therapeutics

Et multicenter, randomiseret, dobbeltblindt, fase 2/3-studie af Ficerafusp Alfa (BCA101) eller placebo i kombination med Pembrolizumab til førstelinjebehandling af PD-L1-positiv, tilbagevendende eller metastatisk planocellulært karcinom i hoved og hals

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).

This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Studieoversigt

Detaljeret beskrivelse

The mechanism of action of ficerafusp alfa involves dual targeting of two cancer targets, EGFR and TGF-β, which are known to drive solid tumor growth and metastasis.

Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:

  • Arm A: ficerafusp alfa 1500 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W).
  • Arm B: ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W.
  • Arm C (control): placebo QW + pembrolizumab 200 mg Q3W.

The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab. Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

650

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Buenos Aires, Argentina, C1190
      • Buenos Aires, Argentina, C1425
      • Pilar, Argentina, B1629ODT
        • Rekruttering
        • Hospital Universitario Austral (Site # 2303)
        • Kontakt:
      • Rosario, Argentina, CP2000
        • Rekruttering
        • Sanatorio de la Mujer (Site # 2305)
        • Kontakt:
      • Santa Fe, Argentina, S2002KDT
        • Rekruttering
        • Hospital Provincial del Centenario (Site # 2302)
        • Kontakt:
    • New South Wales
      • Camperdown, New South Wales, Australien, 2050
        • Rekruttering
        • Chris O'Brien Lifehouse (Site#0302)
        • Kontakt:
      • Kingswood, New South Wales, Australien, 2747
        • Rekruttering
        • Nepean Hospital (Site #0306)
        • Kontakt:
      • Waratah, New South Wales, Australien, 2298
        • Rekruttering
        • Calvary Mater Newcastle (Site#0304)
        • Kontakt:
    • Queensland
      • Southport, Queensland, Australien, 4215
        • Rekruttering
        • Gold Coast University Hospital (Site #0305)
        • Kontakt:
      • Tugun, Queensland, Australien, 4224
        • Rekruttering
        • John Flynn Private Hospital (Site#0307)
        • Kontakt:
    • Victoria
      • Heidelberg, Victoria, Australien, 3084
      • North Melbourne, Victoria, Australien, 3051
        • Rekruttering
        • Peter Macallum Cancer Centre (Site#0301)
        • Kontakt:
    • Western Australia
      • Murdoch, Western Australia, Australien, 6150
        • Rekruttering
        • Fiona Stanley Hospital (Site#0308)
        • Kontakt:
      • Bruges, Belgien, 8000
        • Rekruttering
        • AZ St-Jan Brugge Oostende av (Campus Sint-Jan) (Site #1007)
        • Kontakt:
      • Mons, Belgien, 7000
        • Rekruttering
        • CHU Ambroise Paré (Site #1005)
        • Kontakt:
      • Namur, Belgien, 5000
        • Rekruttering
        • CHU UCL Namur, Site Ste. Elisabeth (Site #1002)
        • Kontakt:
      • Namur, Belgien, 5530
        • Rekruttering
        • CHU UCL Namur, Site Mont-Godinne (Site #1003)
        • Kontakt:
      • Sint-Niklaas, Belgien, 9100
      • Wilrijk, Belgien, 2610
      • Barretos, Brasilien, 14784-400
        • Rekruttering
        • Hospital de Amor de Barretos - Fundação Pio XII (Site # 2413)
        • Kontakt:
      • Belém, Brasilien, 66063495
        • Rekruttering
        • Centro de Tratamento Oncologico (Site # 2421)
        • Kontakt:
      • Curitiba, Brasilien, 80810-050
        • Rekruttering
        • CIONC-Centro Integrado de Oncologia de Curitiba (Site # 2404)
        • Kontakt:
      • Fortaleza, Brasilien, 60430235
        • Rekruttering
        • Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará (Site # 2414)
        • Kontakt:
      • Ijuí, Brasilien, 98700-000
        • Rekruttering
        • Oncosite - Centro de Pesquisa Clinica e Oncologia (Site # 2402)
        • Kontakt:
      • Jaú, Brasilien, 17210-120
        • Rekruttering
        • Fundação Doutor Amaral Carvalho (Site # 2411)
        • Kontakt:
      • Natal, Brasilien, 59062-000
        • Rekruttering
        • Liga Norte-Rio-Grandense Contra o Câncer (Site # 2422)
        • Kontakt:
      • Passo Fundo, Brasilien, 99010-260
        • Rekruttering
        • Hospital de Clínicas de Passo Fundo (Site # 2419)
        • Kontakt:
      • Porto Alegre, Brasilien, 91350-200
        • Rekruttering
        • Hospital Nossa Senhora da Conceicao (Site # 2403)
        • Kontakt:
      • Rio de Janeiro, Brasilien, 22250-905
        • Rekruttering
        • Grupo Oncoclínicas (Site # 2412)
        • Kontakt:
      • Santa Cruz do Sul, Brasilien, 96835-100
        • Rekruttering
        • Hospital Ana Nery (Site # 2415)
        • Kontakt:
      • Santa Lúcia, Brasilien, 30360680
        • Rekruttering
        • Oncoclinicas do Brasil Serviços Médicos S.A - Oncocentro BH (Site # 2401)
        • Kontakt:
      • São Caetano do Sul, Brasilien, 09541-270
        • Rekruttering
        • Centro de Oncologia do ABC - Unidade Santo Andre (Site # 2410)
        • Kontakt:
      • São José do Rio Preto, Brasilien, 15090-000
        • Rekruttering
        • Centro Integrado de Pesquisa do Hospital de Base de São José do Rio Preto/FUNFAR (Site # 2406)
        • Kontakt:
      • São Paulo, Brasilien, 01246-000
        • Rekruttering
        • Instituto do Cancer do Estado de Sao Paulo (ICESP) (Site # 2417)
        • Kontakt:
      • São Paulo, Brasilien, 01509-900
        • Rekruttering
        • A. C. Camargo Cancer Center (Site # 2409)
        • Kontakt:
      • São Paulo, Brasilien, 04014-002
        • Rekruttering
        • IBCC Núcleo de Pesquisa e Ensino (Site # 2405)
        • Kontakt:
      • São Paulo, Brasilien, 04543
        • Rekruttering
        • Oncoclínicas - SP (Site # 2416)
        • Kontakt:
      • São Paulo, Brasilien, 08270-120
        • Rekruttering
        • Hospital Santa Marcelina (Site # 2418)
        • Kontakt:
    • Vitoria ES
      • Santa Cecília, Vitoria ES, Brasilien, 29043-260
        • Rekruttering
        • AFECC Hospital Santa Rita de Cassia (Site # 2420)
        • Kontakt:
      • Toronto, Canada, M4N 3M5
        • Rekruttering
        • Sunnybrook Health Sciences Centre (Site # 0204)
        • Kontakt:
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Rekruttering
        • BC Cancer - Vancouver (Site #0202)
        • Kontakt:
    • Quebec
      • Montreal, Quebec, Canada, H2X 0C1
        • Rekruttering
        • Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame (Site #0203)
        • Kontakt:
      • Aberdeen, Det Forenede Kongerige, AB25 2ZN
        • Rekruttering
        • Aberdeen Royal Infirmary (Site #0504)
        • Kontakt:
      • Birmingham, Det Forenede Kongerige, B15 2TH
        • Rekruttering
        • University Hospitals Birmingham (Queen Elizabeth Hospital) (Site #0512)
        • Kontakt:
      • Cambridge, Det Forenede Kongerige, CB2 0QQ
        • Rekruttering
        • Cambridge University Hospitals (Site #0513)
        • Kontakt:
      • Glasgow, Det Forenede Kongerige, G12 0YN
        • Rekruttering
        • Beatson West of Scotland Cancer Centre (Site # 0510)
        • Kontakt:
      • Leeds, Det Forenede Kongerige, LS9 7TF
        • Rekruttering
        • St James University Hospital Leeds (Site #0511)
        • Kontakt:
      • Liverpool, Det Forenede Kongerige, L7 8YA
        • Rekruttering
        • Clatterbridge Cancer Center NHS Foundation (Site #0507)
        • Kontakt:
      • London, Det Forenede Kongerige, SW3 6JJ
        • Rekruttering
        • Royal Marsden Hospital - Chelsea (Site #0505)
        • Kontakt:
      • London, Det Forenede Kongerige, WC1E 6AG
        • Rekruttering
        • University College London Hospital (Site #0502)
        • Kontakt:
      • Manchester, Det Forenede Kongerige, M20 4BX
        • Rekruttering
        • The Christie Hospital (Site #0508)
        • Kontakt:
      • Middlesex, Det Forenede Kongerige, HA6 2RN
        • Rekruttering
        • Mount Vernon Cancer Centre (Site #0506)
        • Kontakt:
      • Newcastle upon Tyne, Det Forenede Kongerige, NE7 7DN
        • Rekruttering
        • Newcastle University (Site # 509)
        • Kontakt:
      • Nottingham, Det Forenede Kongerige, NG5 1PB
        • Rekruttering
        • Nottingham University Hospitals City Campus (Site #0503)
        • Kontakt:
      • Oxford, Det Forenede Kongerige, OX3 7LE
        • Rekruttering
        • Churchill Hospital (Site #0515)
        • Kontakt:
      • Portsmouth, Det Forenede Kongerige, PO6 3LY
        • Rekruttering
        • Queen Alexandra Hospital (Site # 0514)
        • Kontakt:
      • Sutton, Det Forenede Kongerige, SM2 5PT
        • Rekruttering
        • Royal Marsden Hospital- London (Site # 0501)
        • Kontakt:
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Rekruttering
        • University of Alabama Hospital (Site # 0137)
        • Kontakt:
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85054
        • Rekruttering
        • Mayo Clinic Hospital (Site #0147)
        • Kontakt:
    • California
      • La Jolla, California, Forenede Stater, 92093
        • Rekruttering
        • UC San Diego Moores Cancer Center (Site #0107)
        • Kontakt:
      • Los Angeles, California, Forenede Stater, 90095
        • Rekruttering
        • UCLA Department of Medicine - Hematology/Oncology (Site #0106)
        • Kontakt:
      • Sacramento, California, Forenede Stater, 95817
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • University of California San Francisco (Site #0130)
        • Kontakt:
      • Stanford, California, Forenede Stater, 94305
        • Rekruttering
        • Stanford Cancer Institute (Site #0150)
        • Kontakt:
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80012
        • Rekruttering
        • Rocky Mountain Cancer Centers, LLP (Site #0122)
        • Kontakt:
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • Rocky Mountain Regional VAMC (Site #0124)
        • Kontakt:
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121)
        • Kontakt:
    • Delaware
      • Newark, Delaware, Forenede Stater, 19713
        • Rekruttering
        • ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127)
        • Kontakt:
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32224
        • Rekruttering
        • Mayo Clinic Florida (Site #0148)
        • Kontakt:
      • Palm Bay, Florida, Forenede Stater, 32901
        • Rekruttering
        • Cancer Care Centers of Brevard (Site #0136)
        • Kontakt:
      • Tampa, Florida, Forenede Stater, 33612
        • Rekruttering
        • Moffit Cancer Center (Site #0105)
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60064
        • Rekruttering
        • Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133)
        • Kontakt:
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • University of Iowa Hospitals & Clinics (Site#0140)
        • Kontakt:
    • Kansas
      • Westwood, Kansas, Forenede Stater, 66205
        • Rekruttering
        • University of Kansas Medical Center Research Institute, Inc. (Site #0149)
        • Kontakt:
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536
        • Rekruttering
        • University of Kentucky, Markey Cancer Center (Site # 109)
        • Kontakt:
      • Louisville, Kentucky, Forenede Stater, 40202
        • Rekruttering
        • Norton Cancer Institute (Site#0111)
        • Kontakt:
      • Louisville, Kentucky, Forenede Stater, 40202
        • Rekruttering
        • The University of Louisville, James Graham Brown Cancer Center (Site#0115)
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Rekruttering
        • University of Maryland Medical Group (Site #0112)
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital (Site #0131)
        • Kontakt:
      • Boston, Massachusetts, Forenede Stater, 02136
        • Rekruttering
        • Dana-Farber Cancer Institute (Site#0101)
        • Kontakt:
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • University of Michigan (Site # 161)
        • Kontakt:
    • Minnesota
      • Maplewood, Minnesota, Forenede Stater, 55109
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic Cancer Center - Rochester (Site #0146)
        • Kontakt:
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine (Site #0114)
        • Kontakt:
    • New Jersey
      • Hackensack, New Jersey, Forenede Stater, 07601
        • Rekruttering
        • Hackensack Meridian Health (Site # 119)
        • Kontakt:
      • Newark, New Jersey, Forenede Stater, 07103
        • Rekruttering
        • Rutgers- Cancer Institute (Site #0145)
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10003
      • New York, New York, Forenede Stater, 10021
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center (Site#0142)
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27703
        • Rekruttering
        • Duke University Health System (Site#0118)
        • Kontakt:
    • Ohio
      • Canton, Ohio, Forenede Stater, 44708
      • Cincinnati, Ohio, Forenede Stater, 45221
        • Rekruttering
        • University of Cincinnati Cancer Institute (Site#0117)
        • Kontakt:
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • University Hospitals Seidman Cancer Center (Site #0151)
        • Kontakt:
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Cleveland Clinic (Site #0108)
        • Kontakt:
    • Oregon
      • Portland, Oregon, Forenede Stater, 97213
        • Rekruttering
        • Providence Portland Medical Center (Site #0113)
        • Kontakt:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15206
        • Rekruttering
        • UPMC Hillman Cancer Center (Site #0103)
        • Kontakt:
      • Pittsburgh, Pennsylvania, Forenede Stater, 15240
        • Rekruttering
        • VA Pittsburgh Healthcare System (Site #0123)
        • Kontakt:
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02903
        • Rekruttering
        • Lifespan Cancer Institute (Site #0132)
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Rekruttering
        • Medical University of South Carolina (MUSC) (Site#0104)
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • SCRI-Oncology Partners (Site#0126)
        • Kontakt:
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • Vanderbilt-Ingram Cancer Center (Site #0116)
        • Kontakt:
    • Texas
      • Houston, Texas, Forenede Stater, 77005
        • Rekruttering
        • MD Anderson Cancer Center (Site#0102)
        • Kontakt:
      • Waco, Texas, Forenede Stater, 676712
        • Rekruttering
        • SCRI- Texas Oncology- Central South (Site #0152)
        • Kontakt:
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22904
        • Rekruttering
        • University of Virginia (Site#0134)
        • Kontakt:
      • Richmond, Virginia, Forenede Stater, 23219
        • Rekruttering
        • Virginia Commonwealth University (VCU) Massey Cancer Center (Site #0129)
        • Kontakt:
      • Richmond, Virginia, Forenede Stater, 23249
        • Rekruttering
        • Richmond Department of Veterans Affairs (Site #0138)
        • Kontakt:
    • Washington
      • Edmonds, Washington, Forenede Stater, 98026
        • Rekruttering
        • Swedish Cancer Institute - North Campus Edmonds (Site # 0160)
        • Kontakt:
      • Seattle, Washington, Forenede Stater, 98104
        • Rekruttering
        • Swedish Cancer Institute (Site # 0159)
        • Kontakt:
      • Seattle, Washington, Forenede Stater, 98109
        • Rekruttering
        • University of Washington - Seattle Cancer Care Alliance (Site #0125)
        • Kontakt:
      • Vancouver, Washington, Forenede Stater, 98684
        • Rekruttering
        • Northwest Cancer Specialists, PC (Site#0120)
        • Kontakt:
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53705
        • Rekruttering
        • William S. Middleton Memorial Veteran's Hospital (Site #0141)
        • Kontakt:
      • Madison, Wisconsin, Forenede Stater, 53792
        • Rekruttering
        • University of Wisconsin Hospital and Clinics (Site #0157)
        • Kontakt:
      • Milwaukee, Wisconsin, Forenede Stater, 53233
        • Rekruttering
        • Advocate Aurora Research Institute (Site # 0153)
        • Kontakt:
      • Amiens, Frankrig, 80480
        • Rekruttering
        • CHU Amiens - Hopital Sud (Site #0809)
        • Kontakt:
      • Bordeaux, Frankrig, 33075
        • Rekruttering
        • CHU de Bordeaux (Site # 0812)
        • Kontakt:
      • Lille, Frankrig, 59000
        • Rekruttering
        • Centre Oscar Lambret (Site # 0804)
        • Kontakt:
      • Lyon, Frankrig, 69004
        • Rekruttering
        • Centre Hospitalier de la Croix Rousse (Site #0810)
        • Kontakt:
      • Paris, Frankrig, 75005
        • Rekruttering
        • Institut Curie - site de Paris (Site # 0813)
        • Kontakt:
      • Rennes, Frankrig, 35042
        • Rekruttering
        • CRLCC Eugene Marquis (Site #0805)
        • Kontakt:
      • Saint-Grégoire, Frankrig, 35760
        • Rekruttering
        • Les Hopitaux Prives Rennais - Saint-Gregoire (Site #0807)
        • Kontakt:
      • Strasbourg, Frankrig, 67200
        • Rekruttering
        • Centre Regional Lutte Contre Le Cancer - PAUL STRAUSS (Site #0808)
        • Kontakt:
      • Toulouse, Frankrig, 31059
      • Vandœuvre-lès-Nancy, Frankrig, 54519
        • Rekruttering
        • ICL - Alexis Vautrin (Site #0806)
        • Kontakt:
      • Villejuif, Frankrig, 94805
        • Rekruttering
        • Institut Gustave Roussy (Site #0801)
        • Kontakt:
      • Athens, Grækenland, 12461
        • Rekruttering
        • U.G.H. ATTIKON - General Hospital of West Attica "H AGIA VARVARA" (Site # 1701)
        • Kontakt:
      • Larissa, Grækenland, 41110
        • Rekruttering
        • University General Hospital of Larissa (Site # 1702)
        • Kontakt:
      • Madurai, Indien, 625107
        • Rekruttering
        • Meenakshi Mission Hospital & Research Centre (Site # 3003)
        • Kontakt:
      • Sūrat, Indien, 395004
        • Rekruttering
        • Nirmal Hospital (Site # 3002)
        • Kontakt:
      • Cork, Irland, T12 DC4A
        • Rekruttering
        • Cork University Hospital - Consultants Private Clinic (Site # 0603)
        • Kontakt:
      • Dublin, Irland, D08 NHY1
        • Rekruttering
        • Trinity College Dublin (TCD) - St. James's Hospital (SJH) (Site #0602)
        • Kontakt:
      • Dublin, Irland, D09 V2N0
        • Rekruttering
        • Beaumont Hospital (Site #0601)
        • Kontakt:
      • Beersheba, Israel, 84101
        • Rekruttering
        • Soroka Medical Center (Site # 1901)
        • Kontakt:
      • Jerusalem, Israel, 9112001
        • Rekruttering
        • Hadassah Medical Center (Site # 1903)
        • Kontakt:
      • Petah Tikva, Israel, 49100
        • Rekruttering
        • Rabin Medical Center (Site # 1904)
        • Kontakt:
      • Tel Aviv, Israel, 6423906
        • Rekruttering
        • Sourasky Medical Center (Site # 1902)
        • Kontakt:
      • Bologna, Italien, 40138
        • Rekruttering
        • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi (Site #0904)
        • Kontakt:
      • Cagliari, Italien, 09121
        • Rekruttering
        • ARNAS G. Brotzu (Site # 913)
        • Kontakt:
      • Florence, Italien, 50134
        • Rekruttering
        • Azienda Ospedaliera Universitaria Careggi (Site #0911)
        • Kontakt:
      • Milan, Italien, 20132
        • Rekruttering
        • Ospedale San Raffaele (Site #0907)
        • Kontakt:
      • Milan, Italien, 20133
        • Rekruttering
        • Fondazione IRCCS Istituto Nazionale dei Tumori (Site #0901)
        • Kontakt:
      • Milan, Italien, 20142
        • Rekruttering
        • ASST Santi Paolo e Carlo, Ospedale San Paolo Polo Universitario (Site #0905)
        • Kontakt:
      • Milan, Italien, 20162
        • Rekruttering
        • Azienda Socio Sanitaria Territoriale Niguarda (Site # 0912)
        • Kontakt:
      • Naples, Italien, 80131
        • Rekruttering
        • Istituto Nazionale Tumori Fondazione G. Pascale (Site #0915)
        • Kontakt:
      • Naples, Italien, 80131
        • Rekruttering
        • UOC Oncoematologia AOU - University Luigi Vanvitelli (Site # 0916)
        • Kontakt:
      • Padova, Italien, 35128
        • Rekruttering
        • IOV - Istituto Oncologico Veneto IRCCS (Site # 0910)
        • Kontakt:
      • Palermo, Italien, 90127
        • Rekruttering
        • Policlinico P. Giaccone di Palermo (Site #0908)
        • Kontakt:
      • Pavia, Italien, 27100
        • Rekruttering
        • Fondazione IRCCS Policlinico San Matteo (Site # 0903)
        • Kontakt:
      • Pisa, Italien, 56126
        • Rekruttering
        • Azienda Ospedaliero Universitaria Pisana (Site # 0909)
        • Kontakt:
      • Rome, Italien, 00161
        • Rekruttering
        • Azienda Ospedaliero-Universitaria Policlinico Umberto I (Site #0917)
        • Kontakt:
      • Rome, Italien, 00168
        • Rekruttering
        • Fondazione Policlinico Universitario - Agostino Gemelli (Site #0918)
        • Kontakt:
      • Rome, Italien, 00186
        • Rekruttering
        • Fatebenefratelli Isola Tiberina, Gemelli Isola (Site #0906)
        • Kontakt:
      • Rozzano, Italien, 20089
        • Rekruttering
        • Humanitas Mirasole S.p.A (Site # 0919)
        • Kontakt:
      • Siena, Italien, 53100
        • Rekruttering
        • A.O.U. Senese Policlinico Santa Maria alle Scotte (Site # 0902)
        • Kontakt:
      • Kōtoku, Japan, 135-8550
        • Rekruttering
        • Cancer Institute Hospital of JFCR (Site # 3107)
        • Kontakt:
      • George Town, Malaysia, 11200
        • Rekruttering
        • Mount Miriam Cancer Hospital (Site # 2802)
        • Kontakt:
      • Kuala Lumpur, Malaysia, 50586
        • Rekruttering
        • Hospital Kuala Lumpur (Site # 2803)
        • Kontakt:
      • Kuala Lumpur, Malaysia, 59100
        • Rekruttering
        • University Malaya Medical centre (Site # 2805)
        • Kontakt:
      • Kuching, Malaysia, 93200
        • Rekruttering
        • Sarawak General Hospital (Site # 2801)
        • Kontakt:
      • Pulau Pinang, Malaysia, 10450
        • Rekruttering
        • Hospital Pulau Pinang (Site # 2804)
        • Kontakt:
      • Christchurch, New Zealand, 8011
        • Rekruttering
        • Christchurch Hospital NZ (Site #0401)
        • Kontakt:
      • Rotorua, New Zealand, 3010
        • Rekruttering
        • Rotorua Hospital (Site#0402)
        • Kontakt:
      • Gdansk, Polen, 80-214
        • Rekruttering
        • UNIWERSYTECKIE CENTRUM KLINICZNE (Site #1401)
        • Kontakt:
      • Gliwice, Polen, 44-102
        • Rekruttering
        • Centrum Onkologii-Instytut im.M.Sklodowskiej Curie (Site # 1405)
        • Kontakt:
      • Katowice, Polen, 40-519
        • Rekruttering
        • Pratia Onkologia Katowice (Site #1403)
        • Kontakt:
      • Konin, Polen, 62-500
        • Rekruttering
        • Przychodnia Lekarska Komed (Site #1407)
        • Kontakt:
      • Krakow, Polen, 31-826
        • Rekruttering
        • Szpital Specjalistyczny im. L.Rydygiera w Krakowie (Site #1404)
        • Kontakt:
      • Siedlce, Polen, 08-110
        • Rekruttering
        • Mazowiecki Szpital Wojewódzki im. sw. Jana Pawla II w Siedlcach Sp. z o.o. (Site #1402)
        • Kontakt:
      • Warsaw, Polen, 02-781
        • Rekruttering
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curiee - Panstwowy Instytut (Site #1406)
        • Kontakt:
      • Braga, Portugal, 4710-243
        • Rekruttering
        • Centro Clínico Académico de Braga (Site #1506)
        • Kontakt:
      • Coimbra, Portugal
        • Rekruttering
        • Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE (Site #1503)
        • Kontakt:
      • Lisbon, Portugal, 1099-023
        • Rekruttering
        • Instituto Português de Oncologia Lisboa (Site #1508)
        • Kontakt:
      • Portimão, Portugal, 8500-338
        • Rekruttering
        • Centro Hospitalar Algarve (Site #1501)
        • Kontakt:
      • Porto, Portugal, 4200-072
        • Rekruttering
        • Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (Site #1505)
        • Kontakt:
      • Porto, Portugal, 4200-319
        • Rekruttering
        • Centro Hospitalar Universitario de Sao Joao (Site #1507)
        • Kontakt:
      • Senhora da Hora, Portugal, 4464-509
        • Rekruttering
        • Unidade Local de Saude de Matosinhos, E.P.E. - Hospital Pedro Hispano (Site #1502)
        • Kontakt:
      • Vila Nova de Gaia, Portugal, 4434-502
        • Rekruttering
        • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E. (Site # 1504)
        • Kontakt:
      • Fribourg, Schweiz, 1752
        • Rekruttering
        • HFR Fribourg Kantonsspital Fribourg (Site # 1803)
        • Kontakt:
      • Geneva, Schweiz, 1205
        • Rekruttering
        • Hopitaux Universitaires de Geneve (Site # 1802)
        • Kontakt:
      • Lausanne, Schweiz, 1011
        • Rekruttering
        • Centre Hospitalier Universitaire Vaudois (CHUV) (Site # 1801)
        • Kontakt:
      • Novena, Singapore, 308433
        • Rekruttering
        • Tan Tock Seng Hospital (Site # 2902)
        • Kontakt:
      • Singapore, Singapore, 168583
        • Rekruttering
        • National Cancer Centre Singapore (Site # 2901)
        • Kontakt:
      • Badalona, Spanien, 8916
        • Rekruttering
        • ICO Badalona - Hospital Universitari Germans Trias i Pujol (Site # 1311)
        • Kontakt:
      • Barcelona, Spanien, 08035
        • Rekruttering
        • Hospital Universitari Vall d'Hebron (Site #1301)
        • Kontakt:
      • Barcelona, Spanien, 08036
        • Rekruttering
        • Hospital Clinic de Barcelona (Site #1305)
        • Kontakt:
      • Barcelona, Spanien, 08041
        • Rekruttering
        • Hospital de la Santa Creu I Sant Pau Site #1304
        • Kontakt:
      • Barcelona, Spanien, 08908
        • Rekruttering
        • Institut Catala d'Oncologia (Site # 1302)
        • Kontakt:
      • Madrid, Spanien, 28027
        • Rekruttering
        • Clinica Universidad de Navarra- Madrid (Site #1310)
        • Kontakt:
      • Madrid, Spanien, 28041
        • Rekruttering
        • Hospital Universitario 12 De Octubre (Site #1303)
        • Kontakt:
      • Pamplona, Spanien, 31008
        • Rekruttering
        • Clinica Universidad de Navarra (Site #1306)
        • Kontakt:
      • Santander, Spanien, 39008
        • Rekruttering
        • Hospital Universitario Marques de Valdecilla (HUMV) (Site #1309)
        • Kontakt:
      • Valencia, Spanien, 46010
        • Rekruttering
        • Hospital Clinico Universitario de Valencia (Site #1307)
        • Kontakt:
      • Valencia, Spanien, 46014
        • Rekruttering
        • Hospital General Universitario de Valencia (Site #1308)
        • Kontakt:
      • Busan, Sydkorea, 49267
        • Rekruttering
        • Kosin University Gospel Hospital (Site # 2707)
        • Kontakt:
      • Goyang-si, Sydkorea, 10408
        • Rekruttering
        • National Cancer Center (Site # 2704)
        • Kontakt:
      • Hwasun, Sydkorea, 58128
        • Rekruttering
        • Chonnam National University Hwasun Hospital (Site # 2705)
        • Kontakt:
      • Seongnam, Sydkorea, 13620
        • Rekruttering
        • Seoul National University Bundang Hospital (Site # 2706)
        • Kontakt:
      • Seoul, Sydkorea, 3080
        • Rekruttering
        • Seoul National University Hospital (Site # 2701)
        • Kontakt:
      • Seoul, Sydkorea, 3722
        • Rekruttering
        • SEVERANCE HOSPITAL, YONSEI UNIVERSITY (Site # 2702)
        • Kontakt:
      • Seoul, Sydkorea, 6351
        • Rekruttering
        • Samsung Medical Center (Site # 2703)
        • Kontakt:
      • Changhua, Taiwan, 50006
        • Rekruttering
        • Changhua Christian Medical Foundation Changhua Christian Hospital (Site # 2602)
        • Kontakt:
      • Kaohsiung City, Taiwan, 807
        • Rekruttering
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (Site # 2601)
        • Kontakt:
      • Taichung, Taiwan, 40447
        • Rekruttering
        • China Medical University Hospital (CMUH) (Site # 2603)
        • Kontakt:
      • Taipei, Taiwan, 10002
        • Rekruttering
        • National Taiwan University Hospital (Site # 2604)
        • Kontakt:
      • Bangkok, Thailand, 10400
        • Rekruttering
        • Phramongkutklao Hospital (Site # 2505)
        • Kontakt:
      • Bangkok, Thailand, 10400
        • Rekruttering
        • Rajavithi Hospital (Site # 2504)
        • Kontakt:
      • Chiang Mai, Thailand, 50200
        • Rekruttering
        • Maharaj Nakorn Chiang Mai Hospital (Site # 2506)
        • Kontakt:
      • Dusit, Thailand, 10300
        • Rekruttering
        • Vajira Hospital (Site # 2503)
        • Kontakt:
      • Hat Yai, Thailand, 90110
        • Rekruttering
        • Songklanagarind Hospital (Site # 2502)
        • Kontakt:
      • Hradec Králové, Tjekkiet, 500 03
        • Rekruttering
        • Fakultni Nemocnice Hradec Kralove (FNHK) (Site # 2101)
        • Kontakt:
      • Prague, Tjekkiet, 15006
        • Rekruttering
        • Fakultni nemocnice Motol a Homolka (Site #2102)
        • Kontakt:
      • Ankara, Tyrkiet (Türkiye), 6100
        • Rekruttering
        • Hacettepe University Medical Faculty (Site # 1201)
        • Kontakt:
      • Ankara, Tyrkiet (Türkiye), 6520
        • Rekruttering
        • Memorial Ankara Hospital (Site # 1202)
        • Kontakt:
      • Antalya, Tyrkiet (Türkiye), 7020
        • Rekruttering
        • Memorial Antalya Hastanesi (Site # 1204)
        • Kontakt:
      • Istanbul, Tyrkiet (Türkiye), 34098
        • Rekruttering
        • Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty (Site # 1203)
        • Kontakt:
      • Izmir, Tyrkiet (Türkiye), 35330
        • Rekruttering
        • Dokuz Eylul University Medical School (Site # 1206)
        • Kontakt:
      • Aachen, Tyskland, 52074
        • Rekruttering
        • Universitaetsklinikum Aachen AOeR (Site #0710)
        • Kontakt:
      • Berlin, Tyskland, 12200
        • Rekruttering
        • Charite - Campus Benjamin Franklin (Site # 0701)
        • Kontakt:
      • Berlin, Tyskland, 12351
        • Rekruttering
        • Vivantes Klinikum Neukoelln (Site # 0714)
        • Kontakt:
      • Braunschweig, Tyskland, 38114
        • Rekruttering
        • Staedtisches Klinikum Braunschweig gGmbH (Site # 0709)
        • Kontakt:
      • Chemnitz, Tyskland, 09116
        • Rekruttering
        • Klinikum Chemnitz gGmbH (Site # 0705)
        • Kontakt:
      • Dresden, Tyskland, 01067
        • Rekruttering
        • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt (Site #0707)
        • Kontakt:
      • Dresden, Tyskland, 01307
        • Rekruttering
        • Universitaetsklinikum Carl Gustav Carus TU Dresden (Site # 0711)
        • Kontakt:
      • Düsseldorf, Tyskland, 40225
        • Rekruttering
        • Heinrich-Heine-Universitaet Duesseldorf (Site #0706)
        • Kontakt:
      • Essen, Tyskland, 45147
        • Rekruttering
        • Universitaetsklinikum Essen (Site # 0716)
        • Kontakt:
      • Göttingen, Tyskland, 37075
        • Rekruttering
        • Universitaetsmedizin Goettingen (Site # 0708)
        • Kontakt:
      • Hanover, Tyskland, 30625
        • Rekruttering
        • Medizinische Hochschule Hannover (Site # 0718)
        • Kontakt:
      • Karlsruhe, Tyskland, 76137
        • Rekruttering
        • Vincentius-Diakonissen-Kliniken gAG/St. Vincentius-Kliniken (Site #0717)
        • Kontakt:
      • München, Tyskland, 81675
        • Rekruttering
        • Technische Universität München School of Medicine (Site # 0715)
        • Kontakt:
      • Stuttgart, Tyskland, 70174
        • Rekruttering
        • Klinikum Stuttgart-Katharinenhospital (Site # 0703)
        • Kontakt:
      • Ulm, Tyskland, 89075
        • Rekruttering
        • Universitaetsklinikum Ulm (Site # 0702)
        • Kontakt:
      • Salzburg, Østrig, 5020
        • Rekruttering
        • Hematology and Medical Oncology, Paracelsus Medical University (Site #1602)
        • Kontakt:
      • Vienna, Østrig, 1090
        • Rekruttering
        • Medical University Vienna (Site #1601)
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥18 years on the day the Informed Consent Form is signed.
  • Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.
  • No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.
  • Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.
  • PD-L1 CPS ≥1.
  • Measurable disease based on RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function, as defined in the protocol.

Exclusion Criteria:

  • Disease suitable for local therapy administered with curative intent.
  • Prior treatment with anti-TGFβ therapy.
  • Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).
  • Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.
  • Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.
  • Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.
  • Life expectancy less than 3 months.
  • Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.
  • Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.
  • Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.
  • Active autoimmune disease requiring systemic treatment in the past 2 years.
  • Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.
  • Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.
  • Known history of human immunodeficiency virus (HIV).
  • Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.
  • Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.
  • Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.
  • Use of a live or live attenuated vaccine within 4 weeks prior to Screening.

Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Phase 2 Arm A

ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)

Investigational

Immunotherapy agent used in combination with investigational agent

Eksperimentel: Phase 2 Arm B

ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W

Investigational

Immunotherapy agent used in combination with investigational agent

Placebo komparator: Phase 2 Arm C

placebo QW + pembrolizumab 200 mg Q3W

Immunotherapy agent used in combination with investigational agent

Placebo Control

Eksperimentel: Phase 3 OBD Arm

ficerafusp alfa OBD + pembrolizumab 200 mg Q3W

Investigational

Immunotherapy agent used in combination with investigational agent

Placebo komparator: Phase 3 Arm C

placebo QW + pembrolizumab 200 mg Q3W

Immunotherapy agent used in combination with investigational agent

Placebo Control

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Tidsramme: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)
Tidsramme: Approximately 1 year.

ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

Approximately 1 year.
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Tidsramme: Approximately 2 years.

ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

Approximately 2 years.
Phase 3 - Overall Survival (OS)
Tidsramme: Approximately 3 years.

OS: Defined as the time from the randomization to death due to any cause.

Approximately 3 years.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Tidsramme: Approximately 1 year.

DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first, per RECIST 1.1 by BICR.

Approximately 1 year.
Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Tidsramme: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.
Tidsramme: Approximately 3 years.

PFS: Defined as the time from randomization to the first documented PD per RECIST 1.1 as determined by BICR or death due to any cause, whichever occurs first.

Approximately 3 years.
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Tidsramme: Approximately 3 years.

ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).

Approximately 3 years.
Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Tidsramme: Approximately 3 years.

DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first per RECIST 1.1 by BICR.

Approximately 3 years.
Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.
Tidsramme: Approximately 3 years.

Clinical Benefit Rate: For subject who demonstrated CR + PR + SD>6 months per RECIST 1.1 by BICR.

Approximately 3 years.
Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.
Tidsramme: Approximately 3 years.

ORR, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.
Tidsramme: Approximately 3 years.

DOR, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.
Tidsramme: Approximately 3 years.

PFS, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - 14. Time to deterioration (TTD) in global health status measured by the EORTC QLQ C30 items for global health status and quality of life scale (item 29/30)
Tidsramme: Approximately 3 years.

To evaluate TTD in global health status/quality of life in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.

TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function.

Approximately 3 years.
Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.
Tidsramme: Approximately 3 years.

To evaluate TTD in pain in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.

TTD defined as the time from first dose (baseline) to change in pain score by 10-point from baseline, using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core Head and Neck Module (EORTC HN35). A higher score indicates a higher level of symptom burden.

Approximately 3 years.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

28. januar 2025

Primær færdiggørelse (Anslået)

1. april 2028

Studieafslutning (Anslået)

1. juli 2029

Datoer for studieregistrering

Først indsendt

10. januar 2025

Først indsendt, der opfyldte QC-kriterier

17. januar 2025

Først opslået (Faktiske)

23. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner